What is SAMAT?
Substance Abuse Medication Assisted Treatment (SAMAT) utilizes Naltrexone (Vivitrol®), a non-addictive opioid antagonist, to treat individuals with Substance Use Disorder (SUD), particularly those suffering from opioid and/or alcohol abuse. The treatment is the only non-opioid developed to combat opioid and alcohol dependence.
In 2015, the Kentucky General Assembly, through SB 192, provided $3 million to the Kentucky Department of Corrections to provide Medically Assisted Treatment (MAT) in conjunction with evidence based Substance Use Disorder treatment for those individuals at risk for heroin and/or heroin relapse upon release from incarceration. Through the use of regularly scheduled Injectable Naltrexone (Vivitrol®), clients are able to eliminate the cravings that lead to heroin and opiate relapse. By maintaining this protocol, clients are best prepared for reentry to the community. There is no cost to the client for these services. Protocol requires enrollment in a jail or prison evidence based Substance Use Disorder program.
What's the difference between Vivitrol® and other SUD MATs?
Some other medically assisted treatments, like Methadone, rely on generating an opiate effect. Others, like Buprenorphine and Suboxone, rely on generating a lessened effect. However, Vivitrol® blocks opiate effects all together. This means that even if an individual uses an opiate while being treated with Vivitrol®, they will not get to enjoy the euphoric effects of the substance.
For more information on SAMATs, please follow the links below:
Click here to read patient stories.
The Criminal Justice Kentucky Treatment Outcome Study (CJKTOS) is a
report prepared for the KY Department of Corrections and the Division of Addiction
Services, based on investigative research conducted by the University of
Kentucky’s Center on Drug and Alcohol Research (CDAR). This annual study shows
the results of SAMAT and data can be accessed through the links below:
CJKTOS 2018 Vivitrol Brief
CJKTOS Employment Brief Report - October 2017
CJKTOS Fiscal Year 2018 Final Report
CJKTOS Fiscal Year 2017 Final Report
Executive Staff Advisor